Checkpoint Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Segment Information (Tables)

Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of significant segment expenses

For the three months ended March 31, 2025 and 2024, the significant expense categories regularly provided to the CODM consisted of the following (in thousands):


	For the three months ended March 31,
	2025		2024
Revenue - related party	$	—	$	—

Operating expenses:
Employee Expenses		2,463		2,109
Stock-based Compensation		1,956		709
Fortress Founder’s Agreement and MSA Expenses		177		521
Manufacturing and Development Expenses		352		4,442
Clinical Expenses		605		1,300
Regulatory Expenses		20		303
License Fees		93		50
Legal & Accounting Expense		3,137		643
R&D Other Expense ⁽¹⁾		134		275
G&A Other Expense ⁽²⁾		2,212		596
Total Operating Expenses		11,149		10,948

Other Segment Items ⁽³⁾		(63)		3
Net Loss	$	(11,212)	$	(10,945)

(1) R&D Other Expense includes travel, consulting, and outside service expenses.

(2) G&A Other Expense includes travel, consulting, marketing, business development, investor relations and, outside services expenses. For 2025, it also includes other Merger related costs, including fees paid to financial advisors.

(3) Other Segment Items include interest income, foreign currency exchange loss, and loss on common stock warrant liabilities.